Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.
drug delivery
drug-repurposing
inflammation
inhalation
non-small cell lung cancer
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
16 Mar 2023
16 Mar 2023
Historique:
received:
13
02
2023
revised:
12
03
2023
accepted:
14
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives.
Identifiants
pubmed: 36986550
pii: ph16030451
doi: 10.3390/ph16030451
pmc: PMC10051080
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Pulm Pharmacol Ther. 2017 Jun;44:50-56
pubmed: 28323056
Cancer Sci. 2020 Oct;111(10):3802-3812
pubmed: 32691974
Nat Rev Immunol. 2014 Oct;14(10):705-11
pubmed: 25190285
Open Access Maced J Med Sci. 2019 Jul 20;7(14):2391-2398
pubmed: 31592285
Pharmacol Ther. 2018 May;185:34-49
pubmed: 29127024
Cell Immunol. 2021 Feb;360:104259
pubmed: 33359760
Int J Med Sci. 2018 Jan 1;15(2):115-123
pubmed: 29333095
Front Immunol. 2021 Nov 05;12:756722
pubmed: 34804043
Cell. 2004 Aug 6;118(3):285-96
pubmed: 15294155
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):16000-5
pubmed: 26668367
J Cancer. 2019 Jun 9;10(15):3435-3443
pubmed: 31293647
Cancer Manag Res. 2018 Oct 15;10:4631-4640
pubmed: 30410398
Biochem Soc Trans. 2019 Dec 20;47(6):1581-1595
pubmed: 31769472
Oncotarget. 2018 Aug 31;9(68):32972-32983
pubmed: 30250643
Biomolecules. 2021 Jul 26;11(8):
pubmed: 34439767
Cancers (Basel). 2022 Feb 24;14(5):
pubmed: 35267492
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Immunol Res. 2019 Jun;7(6):990-1000
pubmed: 30975694
J Hematol Oncol. 2019 Oct 22;12(1):105
pubmed: 31640764
J Immunol. 2016 Mar 1;196(5):2283-92
pubmed: 26826241
PLoS One. 2012;7(2):e30820
pubmed: 22319590
Cancers (Basel). 2020 Jun 29;12(7):
pubmed: 32610705
Int Immunopharmacol. 2010 Jul;10(7):777-83
pubmed: 20399910
Curr Oncol Rep. 2019 Jan 22;21(1):6
pubmed: 30671662
Ann Transl Med. 2021 Nov;9(22):1701
pubmed: 34988210
Oncol Lett. 2019 May;17(5):4263-4270
pubmed: 30944620
Cancer Res. 2016 Jun 1;76(11):3189-99
pubmed: 27197187
PLoS One. 2015 Dec 10;10(12):e0144462
pubmed: 26656720
Molecules. 2022 Feb 22;27(5):
pubmed: 35268581
Respir Res. 2020 May 19;21(1):118
pubmed: 32429927
J Cell Mol Med. 2021 Jun;25(12):5457-5469
pubmed: 33943003
Sci Rep. 2018 Aug 20;8(1):12471
pubmed: 30127400
J Control Release. 2010 Dec 20;148(3):303-10
pubmed: 20869410
JAKSTAT. 2015 Jan 20;3(4):e999503
pubmed: 26413424
Carcinogenesis. 2020 Aug 12;41(8):1123-1133
pubmed: 31740942
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40
pubmed: 20713723
Arch Med Sci. 2021 Mar 18;18(1):141-152
pubmed: 35154535
Br J Cancer. 2022 Sep;127(5):785-787
pubmed: 35739301
Oncotarget. 2016 Jun 28;7(26):39363-39375
pubmed: 27276704
Front Cell Dev Biol. 2022 Mar 17;10:859863
pubmed: 35372327
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
Front Pharmacol. 2021 Apr 21;12:596652
pubmed: 33967748
Oncologist. 2006 Apr;11(4):397-408
pubmed: 16614236
Comb Chem High Throughput Screen. 2021;24(8):1243-1250
pubmed: 32933455
J Exp Med. 2018 Dec 3;215(12):3115-3135
pubmed: 30487290
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
J Leukoc Biol. 2020 Dec;108(6):1747-1764
pubmed: 32991757
Biochim Biophys Acta. 2014 Apr;1845(2):136-54
pubmed: 24388873
Front Immunol. 2022 Apr 20;13:859738
pubmed: 35514957
Biomed Pharmacother. 2020 May;125:109946
pubmed: 32004976
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Sci Transl Med. 2019 Sep 25;11(511):
pubmed: 31554740
Oncoimmunology. 2021 Dec 30;11(1):2010905
pubmed: 35481284
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Am J Respir Cell Mol Biol. 2005 Apr;32(4):311-8
pubmed: 15668323
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
Int J Mol Sci. 2020 Dec 18;21(24):
pubmed: 33352854
Cancers (Basel). 2021 Jun 10;13(12):
pubmed: 34200786
Compr Rev Food Sci Food Saf. 2021 Mar;20(2):1280-1306
pubmed: 33665991
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3876-86
pubmed: 25120764
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Cancer Lett. 2020 Oct 10;490:174-185
pubmed: 32721551
J Control Release. 2022 Jan;341:1-15
pubmed: 34780880
Cancer Cell. 2010 Jan 19;17(1):89-97
pubmed: 20129250
Clin Cancer Res. 2014 Nov 15;20(22):5697-707
pubmed: 25224278
J Clin Med. 2022 May 24;11(11):
pubmed: 35683340
Toxicol Appl Pharmacol. 2016 Nov 1;310:78-86
pubmed: 27639426
J Cancer. 2020 Apr 7;11(14):4123-4131
pubmed: 32368295
Ann Transl Med. 2019 Oct;7(20):572
pubmed: 31807553
Eur J Pharm Biopharm. 2014 Jan;86(1):1-6
pubmed: 24300444
Front Immunol. 2021 Feb 01;11:619257
pubmed: 33603750
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759728
Adv Nutr. 2021 Jun 1;12(3):850-864
pubmed: 33179051
Cancer Cell Int. 2019 Nov 14;19:295
pubmed: 31807117
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Nat Rev Drug Discov. 2007 Jan;6(1):67-74
pubmed: 17195033
Front Immunol. 2019 Oct 04;10:2298
pubmed: 31636634
Mol Oncol. 2021 Oct;15(10):2544-2564
pubmed: 33252175
Curr Opin Hematol. 2018 Jan;25(1):44-51
pubmed: 28914666
Front Pharmacol. 2021 May 11;12:652860
pubmed: 34045963
Autoimmun Rev. 2020 Jul;19(7):102565
pubmed: 32376403
Int J Mol Sci. 2021 Oct 07;22(19):
pubmed: 34639167
Cell Mol Immunol. 2018 Apr;15(4):335-345
pubmed: 29375123
Chem Biol Interact. 2019 Aug 25;309:108720
pubmed: 31226287
J Thorac Oncol. 2018 Mar;13(3):399-412
pubmed: 29233790
Cancer Res. 2007 Oct 15;67(20):9825-34
pubmed: 17942913
Eur J Pharmacol. 2004 Sep 13;498(1-3):45-52
pubmed: 15363974
Sci Rep. 2015 Sep 24;5:14273
pubmed: 26399191
Cancer Immunol Immunother. 2021 Jul;70(7):1867-1876
pubmed: 33394095
Biology (Basel). 2022 Feb 26;11(3):
pubmed: 35336746
Curr Oncol Rep. 2020 Jun 4;22(6):62
pubmed: 32495112
Mol Cancer. 2020 Sep 24;19(1):145
pubmed: 32972405
J Cell Physiol. 2020 Dec;235(12):9241-9268
pubmed: 32519340
Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30
pubmed: 26583808
Molecules. 2020 Dec 22;26(1):
pubmed: 33374961
Curr Med Sci. 2020 Dec;40(6):1075-1084
pubmed: 33428135
Molecules. 2020 Feb 07;25(3):
pubmed: 32046055
Cancer Growth Metastasis. 2017 Dec 21;10:1179064417745539
pubmed: 29308014
Aging (Albany NY). 2019 Nov 6;11(21):9310-9327
pubmed: 31692453
Expert Opin Drug Discov. 2020 Apr;15(4):397-401
pubmed: 31847616
Nutrients. 2022 Jun 10;14(12):
pubmed: 35745143
Ann Gastroenterol. 2012;25(2):106-118
pubmed: 24713845
Respir Res. 2020 Jul 8;21(1):175
pubmed: 32641036
Biomarkers. 2022 Jul;27(5):441-447
pubmed: 35297277
Oncotarget. 2017 Jun 28;8(53):90925-90947
pubmed: 29207614
Nat Rev Rheumatol. 2020 Jun;16(6):335-345
pubmed: 32327746
Cancers (Basel). 2018 Jul 04;10(7):
pubmed: 29973561
Cell. 2019 Feb 21;176(5):998-1013.e16
pubmed: 30712876
Ann Transl Med. 2021 Jul;9(14):1186
pubmed: 34430627
Biomedicines. 2022 Aug 31;10(9):
pubmed: 36140237
Pharmaceuticals (Basel). 2020 Oct 13;13(10):
pubmed: 33066228
Anticancer Agents Med Chem. 2019;19(13):1633-1641
pubmed: 31272362
Adv Exp Med Biol. 2021;1327:191-195
pubmed: 34279839
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Jun;32(6):784-8
pubmed: 27371847
J Control Release. 2019 Nov 28;314:48-61
pubmed: 31644935
Adv Drug Deliv Rev. 2018 Aug;133:107-130
pubmed: 30189271
Cancers (Basel). 2021 Oct 25;13(21):
pubmed: 34771511
Int J Mol Sci. 2020 Aug 28;21(17):
pubmed: 32872198
Oncogene. 2013 Oct 10;32(41):4892-902
pubmed: 23178494
Front Pharmacol. 2021 May 17;12:688625
pubmed: 34079469
Oncotarget. 2017 Jun 28;8(44):76116-76128
pubmed: 29100297
Clin Cancer Res. 2018 Sep 1;24(17):4089-4097
pubmed: 30018118
Sci Rep. 2021 Jul 21;11(1):14862
pubmed: 34290382
Cancer Res. 2015 Aug 15;75(16):3209-15
pubmed: 26122841
Ann Afr Med. 2019 Jul-Sep;18(3):121-126
pubmed: 31417011
Front Pharmacol. 2020 Aug 26;11:1247
pubmed: 32982723
Transl Lung Cancer Res. 2021 Mar;10(3):1444-1456
pubmed: 33889521
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
Sci Rep. 2021 Jan 22;11(1):2097
pubmed: 33483550
J Autoimmun. 2010 May;34(3):J258-65
pubmed: 20042314
Cancer Res. 2006 Apr 15;66(8):4198-207
pubmed: 16618742
Pharmaceuticals (Basel). 2020 Dec 26;14(1):
pubmed: 33375288
Clin Immunol. 2013 Jun;147(3):242-75
pubmed: 23697917
Inflamm Regen. 2019 Jun 6;39:12
pubmed: 31182982
J Control Release. 2018 Dec 10;291:116-126
pubmed: 30321577
Cytokine. 2022 May;153:155850
pubmed: 35279620
Pharmaceuticals (Basel). 2020 Nov 09;13(11):
pubmed: 33182254
BMC Cancer. 2018 May 22;18(1):579
pubmed: 29783929
Medicina (Kaunas). 2018 Mar 25;54(1):
pubmed: 30344239
Evid Based Complement Alternat Med. 2018 Oct 8;2018:7591348
pubmed: 30402133
Eur J Pharm Sci. 2018 Feb 15;113:41-52
pubmed: 29079338
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
J Thorac Oncol. 2011 Dec;6(12):2104-11
pubmed: 21892101
Biochem Pharmacol. 2020 Oct;180:114147
pubmed: 32653589
Lancet Rheumatol. 2022 Jan;4(1):e24-e32
pubmed: 34812424
Cancer Microenviron. 2015 Dec;8(3):125-58
pubmed: 24895166
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997286
Front Cell Dev Biol. 2021 Jun 23;9:643525
pubmed: 34249905
Pharmaceuticals (Basel). 2020 Nov 07;13(11):
pubmed: 33171712
Sci Rep. 2019 Jul 17;9(1):10353
pubmed: 31316109
Adv Drug Deliv Rev. 2018 Aug;133:93-106
pubmed: 29890243
Curr Osteoporos Rep. 2019 Dec;17(6):538-547
pubmed: 31713180
Cancer Immunol Immunother. 2013 Feb;62(2):337-45
pubmed: 22923190
J Korean Med Sci. 2012 Feb;27(2):128-34
pubmed: 22323858
Am J Epidemiol. 2017 Jan 15;185(2):86-95
pubmed: 27998891
Eur J Pharm Sci. 2019 Nov 1;139:105065
pubmed: 31493448
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
Cell Metab. 2020 Oct 6;32(4):524-536
pubmed: 32853548
Drug Deliv Transl Res. 2021 Oct;11(5):1829-1848
pubmed: 33188495
Cell Cycle. 2013 Sep 1;12(17):2839-48
pubmed: 23966159
Biol Pharm Bull. 2021;44(1):39-45
pubmed: 33390548